Spermosens

The clinical study at the Reproductive Medicine Center in Malmö is progressing well, with 68 couples recruited and JUNO binding analysis completed in 51 cases. The company is on track to meet its clinical goals and expects to finish the study by the end of 2025. Interim results show a correlation between JUNO binding and fertilization outcomes, supporting the potential of JUNO-Checked as a diagnostic tool in reproductive treatments. Spermosens is in discussions with potential commercial partners in Europe, the US, and Japan. They have strengthened their US and European business development efforts and are working towards a license agreement in Japan. The company recently secured strategic investments from European and US investors to support its strategy. CEO Tore Duvold is optimistic about achieving clinical goals and securing partnerships. Spermosens will continue to provide updates on the study and commercial discussions. Spermosens AB is a Swedish biotechnology company focused on fertility treatments, with its shares traded on the Spotlight Stock Market.

The study has recruited 52 couples to date, with JUNO binding analysis completed in 37 cases. Interim results indicate that higher JUNO binding, which reflects sperm's ability to bind to the egg, is positively correlated with successful fertilization and pregnancy. Low or absent JUNO binding is associated with failed fertilization, highlighting the JUNO-Checked technology's potential as a diagnostic tool in assisted reproductive treatments. These findings suggest that JUNO-Checked can help identify sperm-related factors in unexplained infertility, especially in cases where standard semen parameters are normal, but fertilization fails. Tore Duvold, CEO of Spermosens, and Dr. Ingela Liljeqvist Soltic, study investigator, both emphasize the technology's potential in improving fertility diagnostics and treatment outcomes. The study aims to complete by 2025, providing solid clinical evidence for JUNO-Checked's diagnostic value. Supported by a SEK 10.8 million investment, Spermosens is focused on clinical validation, technical enhancements, and commercialization. The company aims for cash flow positivity by the second half of 2026 and is well-positioned to create value for patients, partners, and shareholders. Spermosens, based in Sweden, specializes in innovative fertility diagnostics and collaborates with research institutions and partners to advance fertility treatments. Their shares are listed on the Spotlight Stock Market.

Dr. Castillo-León has joined Spermosens as CTO starting April 1st. With over 20 years in biomedical engineering, he will focus on developing JUNO-Checked for commercial success. Dr. Castillo-León, who holds a Ph.D. from Lund University, previously worked at DTU on biomedical diagnostics projects. He will lead efforts to enhance JUNO-Checked's accuracy and integration, collaborating with partners like FlexMedical Solutions and PalmSens to secure licensing deals. Spermosens' CEO, Tore Duvold, emphasized the importance of Dr. Castillo-León's expertise in refining the technology and forming partnerships. Dr. Castillo-León expressed excitement about contributing to reproductive healthcare and the commercialization of JUNO-Checked. His appointment follows a SEK 10.8 million investment aimed at accelerating product and business development. Spermosens, a Swedish biotechnology company, focuses on fertility diagnostics and is listed on the Spotlight Stock Market under the name SPERM.

Spermosens AB and Scalania AG have entered into a collaboration to enhance the development of Spermosens' JUNO-Checked technology, focusing on market strategy, regulatory processes, and business development. Scalania will provide strategic support through its team of experts with extensive experience in market strategy and regulatory affairs. The partnership aims to strengthen Spermosens' market positioning and regulatory navigation, contributing to the growth of their fertility diagnostics solutions. Spermosens, a Swedish biotechnology company, specializes in innovative fertility diagnostics, while Scalania, part of the UNITY Innovation Alliance, offers strategic support to MedTech companies.

The article discusses the JUNO-Checked biosensor, which measures sperm binding to a JUNO-functionalized surface using the JUNOScore. This technology offers insights into sperm function that traditional semen analysis cannot, potentially improving clinical diagnostics and personalized reproductive treatments. Developed in collaboration with the Reproductive Medicines Center in Malmö and FlexMedical Solutions in the UK, Spermosens is conducting a clinical study to validate the biosensor's use in fertility diagnostics. The company has also secured a strategic investment to advance its development and foster partnerships. Tore Duvold, CEO of Spermosens, expressed satisfaction with the publication of their research, emphasizing its significance in reproductive medicine. Spermosens AB, a Swedish biotechnology company, focuses on innovative fertility diagnostics and is listed on the Spotlight Stock Market.

Spermosens has received a strategic investment of SEK 10.8 million from investors in Germany, Scandinavia, and the United States, which will strengthen its financial position and support the development of its JUNO-Checked technology in the ART market. A clinical study at the Reproductive Medicine Center in Malmö has shown promising interim results, indicating a positive correlation between JUNO binding and improved fertilization and pregnancy outcomes. The study aims to present interim results quarterly and conclude in 2025. Spermosens plans to secure licensing agreements after optimizing the technology. The company is working on product customization and technology maturation to make JUNO-Checked commercially viable. Discussions with potential partners in key markets are underway, and Spermosens aims to achieve positive cash flow by the second half of 2026. CEO Tore Duvold emphasizes the strategic investment as a crucial step in advancing their technology and forming global partnerships to address infertility challenges.

The subscription price for TO3 warrants was set at SEK 0.13, but no subscriptions were received as the price exceeded the market value. Consequently, there will be no increase in share capital or dilution for existing shareholders. Spermosens recently secured SEK 10.8 million from a directed share issue by a consortium of strategic investors, ensuring funding until the second half of 2026, when the company expects to achieve cash flow positivity through revenue from license agreements in the global Assisted Reproductive Technology market. Upcoming TO5 and TO6 warrants will be exercisable in June 2025 and November 2026, respectively. Spermosens AB, based in Sweden, is a biotechnology company focused on improving fertility treatments through innovative diagnostic solutions, with its shares traded on the Spotlight Stock Market.

The Board of Directors of Spermosens has decided to conduct a directed share issue, authorized by an extraordinary general meeting, raising SEK 10.8 million by issuing approximately 1.35 billion new shares at SEK 0.0080 per share. This funding is expected to support the company until the second half of 2026, when it aims to achieve cash flow positivity through license agreements in the global Assisted Reproductive Technology market. The investment consortium is led by Mount Nebo Capital and includes UNITY Innovation Alliance and seven Nordic and German institutional investors and family offices. UIA will provide strategic and operational advice, aiding in product development and market strategy. The funds will be used for clinical studies, technology optimization, validation, and business development. The decision to proceed with a directed share issue, rather than a rights issue, was made after considering various financing options. Spermosens, a biotechnology company focused on fertility diagnostics, aims to enhance fertility treatments with its JUNO-Checked product. Advisors for the transaction include Scalania AG, Bergs Securities AB, and Fram Advokatbyrå.